We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

IAG:ASXInsurance Australia Group Ltd Analysis

Data as of 2026-03-13 - not real-time

A$7.25

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Insurance Australia Group is trading below its 20‑day SMA but above the 50‑day SMA, signalling a short‑term bearish bias despite a recent bullish MACD histogram. Revenue growth of roughly 10% and a solid dividend yield of over 4% underpin the defensive appeal, while the recent 6% premium increase hints at pricing power but also foreshadows further premium pressure from inflation. Analysts remain optimistic, rating the stock as a buy with a median target near $8.1, yet the DCF fair value of about $5.8 suggests the market is pricing in significant upside risk.
The balance sheet shows moderate leverage (debt‑to‑equity ~42%) and a healthy operating cash flow, though free cash flow is negative, raising questions about dividend sustainability. Volatility remains elevated at nearly 39% over the past month, but the ultra‑low beta (~0.09) indicates limited systematic risk. Overall, the stock appears overvalued relative to intrinsic estimates, but its high dividend and stable earnings make it attractive for income‑focused investors willing to tolerate short‑term price weakness.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bearish technical trend with price below 20‑day SMA
  • Current price above DCF fair value
  • Elevated short‑term volatility

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Continued premium growth offset by inflation‑driven pricing power
  • Attractive dividend yield and reasonable payout ratio
  • Analyst consensus buy recommendation and target price above current level

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Defensive business model with stable cash flows
  • Low beta and limited currency exposure
  • Overvaluation relative to intrinsic value may limit upside

Key Metrics & Analysis

Financial Health

Revenue Growth10.30%
Profit Margin5.95%
P/E Ratio15.8
ROE15.74%
ROA4.59%
Debt/Equity41.71
P/B Ratio2.3
Op. Cash FlowA$1.1B
Free Cash FlowA$-396624992
Industry P/E16.4

Technical Analysis

TrendBearish
RSI59.7
SupportA$6.39
ResistanceA$7.29
MA 20A$6.77
MA 50A$7.25
MA 200A$8.07
MACDBullish
VolumeStable
Fear & Greed Index72.88

Valuation

Fair ValueA$5.79
Target PriceA$8.24
Upside/Downside13.60%
GradeOvervalued
TypeBlend
Dividend Yield4.28%

Risk Assessment

Beta0.17
Volatility38.97%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.